Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors
Treatment of relapsed/refractory multiple myeloma (RRMM) is more complex today due to the availability of novel therapeutic options, mostly applied as combination regimens. immunotherapy options have especially increased substantially, likewise the understanding that patient-, disease- and treatment...
Main Authors: | Laura Gengenbach, Giulia Graziani, Heike Reinhardt, Amelie Rösner, Magdalena Braun, Mandy-Deborah Möller, Christine Greil, Ralph Wäsch, Monika Engelhardt |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/17/4320 |
Similar Items
-
Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab
by: Chen WC, et al.
Published: (2017-07-01) -
Treatment of relapsed refractory multiple myeloma: which new PI-based combination treatments do patients prefer?
by: Wilke T, et al.
Published: (2018-11-01) -
Bendamustine in patients with relapsed or refractory multiple myeloma
by: Michael M, et al.
Published: (2010-01-01) -
How I treat relapsed and/or refractory multiple myeloma
by: Hans C. Lee, et al.
Published: (2020-09-01) -
Carfilzomib for relapsed and refractory multiple myeloma
by: Groen K, et al.
Published: (2019-04-01)